New: NCI-funded clinical trial search
Mednet Logo
SpecialtiesRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

How would you counsel a patient concerned about receiving IMRT rather than IMPT for oropharyngeal cancer?

10
7 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

I would tell the patient there is absolutely no concern at all with IMRT, and it is a very well-established SOC. I am personally unclear about the OS benefit with IMPT, as it was pointed out, unexpected. It is unusual to see no difference in PFS and no tox difference, and yet there is an OS differen...

Are there any alternative, hypofractionated RT courses for patients with DLBCL that can be used during the COVID-19 pandemic?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · David Geffen School of Medicine at UCLA

ILROG recently came out with guidelines pasted below: Synopsis of ILROG Recommendations for Administering Radiotherapy for Hematological Malignancies During Emergency Conditions of the COVID-19 Pandemic • We are facing an increased demand for RT to substitute or complement systemic therapy deemed i...

Is there any situation where hypofractionation of post-mastectomy radiation (CW and regional nodes) is absolutely contraindicated?

1
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

While not absolute given some phase 2 data, I am not currently offering hypofractionated PMRT to patients with reconstruction, as I am awaiting results of the Alliance trial. I do offer hypofractionated PMRT to patients who are not undergoing reconstruction. However, I am cautious in patients with c...

How do you incorporate PCI into your management of patients with extensive stage SCLC?

8
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Colorado School of Medicine

I must admit, that I was never a fan of PCI in the extensive SCLC setting. With the publication of the Japanese study, I am definitely not strongly recommending PCI. I think it is good to see the patient so that we can discuss both PCI and thoracic consolidation, but I have been doing more thoracic ...

How would you manage a small posterior vaginal defect noted at the time of cervical brachytherapy?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

If it is from a disease, I would continue brachy as planned and address the defect based on response and healing. If unrelated to disease, I would have it sutured and continue brachy as planned.

Would you use radiation to treat a persistent VIN III lesion that involves the urethral meatus and has recurred multiple times despite ablation and resection?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Kentucky

I think that the "standard" answer would be to wait until the invasion is documented. Having said that, I would seriously consider a Cs-131 interstitial implant to the area, delivering a dose to total decay of 55 Gy. I have not done exactly this, but I have implanted VIN III adjacent to a positive r...

How do you manage moderate chest wall pain after breast radiation if imaging studies are normal?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Beth Israel Deaconess Medical Center

Pain in the breast or chest wall due to RT-induced myositis or fibrosis is generally mild and responds to nonsteroidal anti-inflammatory agents and stretching exercises. However, one should first determine whether there is a cause of pain separate from RT effects. One of the common sources of such c...

Are CHEK2 mutations a contraindication for breast conservation therapy with lumpectomy + RT?

3
4 Answers

Mednet Member
Mednet Member
Medical Oncology · Columbia University Medical Center

Among women with early-stage breast cancer and moderate penetrance breast cancer susceptibility genes, such as CHEK2, decisions about breast surgery are largely based upon personal preferences. According to data from large population-based studies, women with CHEK2 pathogenic variants have about a 2...

In a patient with inflammatory triple-positive breast cancer who has a pCR to neoadjuvant chemotherapy, but has an incidentally found focus of intermediate-grade ER+/PR+/HER2- ILC in the mastectomy specimen, how would this impact your adjuvant radiation recommendations?

3
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Beth Israel Deaconess Medical Center

This finding would not have any impact on my recommendations, since her management needs to be guided by the inflammatory breast cancer. That means chest wall plus nodal irradiation tailored to the findings of axillary surgery. There are no data on whether we can decrease the dose in patients with a...

How would you advise a younger patient with residual/recurrent optic nerve meningioma, proceeding with radiotherapy, about the risks of malignant transformation or induction of other brain malignancies because of radiation?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · GammaWest Cancer Services

The risk of malignant transformation of an optic nerve sheath meningioma (ONSM) after RT appears to be remarkably low, much lower than the risk of blindness from an untreated, progressive ONSM. In a younger patient, I would lean toward RT for patients with imaging progression or early visual loss, ...